



Lotus Eye Hospital And Institute Limited

CIN No. : L85110TZ1997PLC007783

770/12, Avinashi Road, Civil Aerodrome Post, Coimbatore - 641 014.

Tel : 0422 - 4229900, 4229999 Fax : 0422 - 4229933



R.S. PURAM

155B, East Periasamy Road, Near Chinthamani,
North Coimbatore, R.S. Puram,
Coimbatore - 2. Phone : 0422 - 4239900, 4239999

METTUPPALAYAM

No. 28, Coimbatore Main Rd,
Opp. Bus Stand, MTP - 634 301.
Phone : 04254 - 223223, 224224

TIRUPUR

No. 5(2) Gajalakshmi Theatre Road (Backside)
Near Valarmathi Bus Stop, Tirupur - 641 601.
Phone : 0421 - 4346060, 4219999

SALEM

86, Brindhavan Road, Fairlands
Salem - 636 004.
Ph. : 0427 - 4219900, 4219999

E-mail : info@lotuseye.org

Website : www.lotuseye.org

May 25, 2022

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Scrip Code: 532998	National Stock Exchange of India Limited 5th Floor, Exchange Plaza Bandra (East) Mumbai – 400 051 Scrip Code: LOTUSEYE
---	---

Dear Madam/Sir

Sub: Audited Standalone Financial Results for the period and year ended March 31 2022

Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("SEBI (LODR)") Audited Standalone Financial Results along with the Audit report for the period and year ended March 31, 2022. The figures were reviewed by Audit Committee in its meeting held on May 25, 2022 and approved by the Board of Directors on May 25, 2022.

Please find Enclosed herewith

1. Audited Standalone Financial Results for the quarter and year ended 31st March 2022
2. Half yearly disclosure as per Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements 2015 for the half year ended 31st March 2022
3. Declaration of Unmodified opinion as per SEBI Circular CIR/CFD/CMD/56/2016 dated May, 27, 2016

We request you to please take the same on your record.

Thanking You.

For Lotus Eye Hospital & Institute Limited

M Achuth Menon
Company Secretary & Compliance Officer
Membership No-A63980

Kochi

533/33A-33F, Tejas Tower
SA Road, Kadavanthara,
Kochi, Kerala - 682 020.
Tel. : 0484 - 2322333, 2322444

Always for you

Kochi

229A, Kurisingal House
Mula:thuruty Post
Kochi, Kerala - 682 314.
Tel. : 0484 - 2743191, 2743121



Lotus Eye Hospital and Institute Limited

CIN: L85110TZ1997PLC007783

Registered office: 770/12, Avinashi road, Aerodrome post, Coimbatore 641 014

Phone no: 0422-4229900, 4229999, Fax: 0422-2627193, E-mail: info@lotuseye.org, Website: www.lotuseye.org

Audited Financial Results for the Quarter and Year Ended March 31,2022

(Rs. In Lakhs)


Sr. No.	Particulars	Quarter Ended			Year Ended	
		31-Mar-22 (Audited)	31-Dec-21 (Un-audited)	31-Mar-21 (Audited)	31-Mar-22 (Audited)	31-Mar-21 (Audited)
	Income:					
I.	Revenue from operations	1,056.88	1,160.80	1,056.70	3,890.99	3,236.90
II.	Other income	28.80	21.53	18.67	88.58	74.25
III.	Total income (I+II)	1,085.69	1,182.33	1,075.37	3,979.57	3,311.15
IV.	Expenses:					
	(a) Cost of materials consumed	188.25	191.14	170.08	651.08	508.89
	(b) Purchase of stock-in-trade	145.15	172.84	149.77	568.82	475.96
	(c) Service expenses	158.80	168.89	165.70	615.58	542.62
	(d) Changes in inventories	2.13	(7.12)	(1.03)	(7.35)	(8.38)
	(e) Employee benefit expense	202.88	197.82	205.97	730.58	697.18
	(f) Finance costs	3.47	3.88	1.10	12.81	5.63
	(g) Depreciation and amortization expense	74.80	63.06	59.39	250.10	233.01
	(h) Other expenses	234.90	202.30	189.34	747.60	665.12
	Total expenses (IV)	1,010.38	992.81	940.32	3,569.22	3,120.04
V.	Profit/(loss) before exceptional items and tax (III-IV)	75.31	189.52	135.05	410.35	191.11
VI.	Exceptional items	(0.79)	-	(0.02)	(1.00)	8.11
VII.	Profit/(loss) before tax (V+VI)	74.52	189.52	135.03	409.35	199.22
VIII.	Tax expenses					
	(a) Current tax	16.35	51.18	24.83	108.57	46.96
	(b) Deferred tax	4.05	(0.23)	(0.51)	2.34	(4.54)
	Total tax expense (VIII)	20.40	50.95	24.32	110.91	42.41
IX.	Net profit/(loss) for the period (VII-VIII)	54.12	138.57	110.71	298.44	156.81
X.	Other comprehensive income, net of income tax					
	A. Items that will not be reclassified to profit or loss					
	- Remeasurement of post-employment defined benefit plans	2.96	(2.50)	(24.71)	(4.54)	(17.71)
	- Income tax on the above item	(0.82)	0.70	6.87	1.26	4.93
	B. Items that will be reclassified to profit or loss	-	-	-	-	-
	Total other comprehensive income, net of income tax (X)	2.14	(1.80)	(17.84)	(3.27)	(12.78)
XI.	Total comprehensive income for the period (IX + X)	56.26	136.77	92.86	295.17	144.03
XII.	Paid-up equity share capital (face value of Rs. 10/- each)	2,079.63	2,079.63	2,079.63	2,079.63	2,079.63
XIII.	Earning per equity share: (of Rs. 10/-) (Not annualised) :					
	(1) Basic (in Rs.)	0.26	0.67	0.53	1.44	0.75
	(2) Diluted (in Rs.)	0.26	0.67	0.53	1.44	0.75

Notes:

- The above results have been reviewed by the Audit committee and approved by the Board of Directors at their meeting held on May 25, 2022. The above results has also been subjected to Audit by statutory auditors of the company.
- Exceptional items represent the gain/(loss) on disposals of items of property, plant and equipment.
- The Board of Directors has recommended a dividend of Rs. 5/- per fully paid equity share of face value of Rs. 10/- for the Financial Year ended 31st March, 2022. The payment of dividend is subject to the approval of the members in the Annual General Meeting.
- The continuance of COVID 19 pandemic has caused significant disturbance and slowdown of economic activities. The Company's operations were impacted.
- Figures of the previous periods have been regrouped and reclassified to confirm to the classification of current period, wherever necessary.
- The figures for quarter ended March 31, 2022 are balancing figures between the audited figures of the full financial year and the limited reviewed year-to-date figures upto third quarter of the financial year.

Coimbatore,
May 25, 2022.

For Lotus Eye Hospital & Institute Limited


Ms. S. SANGEETHA
Managing Director - DIN : 01859252

Lotus Eye Hospital and Institute Limited
CIN: L85110TZ1997PLC007783

Registered office: 770/12, Avinashi road, Aerodrome post, Coimbatore 641 014
Phone no: 0422-4229900, 4229999, Fax: 0422-2627193, E-mail: info@lotuseye.org
Website: www.lotuseye.org

Audited Balance Sheet as at March 31,2022

	(Rs. In Lakhs)	
Particulars	As at March 31,2022 (Audited)	As at March 31,2021 (Audited)
Assets		
1. Non-current assets		
(a) Property, plant and equipment	4,197.49	3,897.75
(b) Right of use asset	197.47	139.73
(c) Intangible assets	12.28	16.31
(d) Deferred tax assets (net)	52.30	77.33
(e) Other non-current assets	413.93	431.38
Total Non-current assets (A)	4,873.47	4,562.51
2. Current assets		
(a) Inventories	230.53	177.95
(b) Financial assets		
(i) Trade receivables	62.05	74.10
(ii) Cash and cash equivalents	378.89	518.07
(iii) Bank balances other than above	505.85	473.25
(c) Other current assets	108.89	117.03
Total Current assets (B)	1,286.21	1,360.40
Total Assets (A + B)	6,159.68	5,922.91
Equity and Liabilities		
1. Equity		
(a) Equity share capital	2,079.63	2,079.63
(b) Other equity	3,381.23	3,190.04
Total Equity (C)	5,460.86	5,269.67
2. Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Lease Liabilities	67.05	13.59
(b) Provisions	34.83	40.26
(c) Other non-current liabilities	21.89	17.63
Total Non-current liabilities (D)	123.77	71.48
Current liabilities		
(a) Financial liabilities		
(i) Trade payables	318.70	283.07
(ii) Lease Liabilities	56.76	26.28
(b) Other current liabilities	199.59	272.41
Total Current liabilities (E)	575.05	581.75
Total Liabilities (D+E)	698.82	653.23
Total Equity and Liabilities (C+D+E)	6,159.68	5,922.91

Coimbatore,
May 25, 2022.

For Lotus Eye Hospital & Institute Limited


Ms. S. SANGEETHA
Managing Director - DIN : 01859252

Lotus Eye Hospital and Institute Limited
CIN: L85110TZ1997PLC007783

Registered office: 770/12, Avinashi road, Aerodrome post, Coimbatore 641 014
Phone no: 0422-4229900, 4229999, Fax: 0422-2627193, E-mail: info@lotuseye.org
Website: www.lotuseye.org

Audited Cash Flow Statement for the year ended March 31,2022

(Rs. In Lakhs)

Particulars	For the year ended March 31, 2022 (Audited)	For the year ended March 31, 2021 (Audited)
A.Cash flows from operating activities		
Profit before tax and exceptional item	410.35	191.11
<i>Adjustments:</i>		
Depreciation and amortisation	250.10	233.01
Interest income	(45.00)	(39.10)
Rental income	(29.75)	(21.50)
Finance costs	12.81	5.63
Operating cash flow before working capital changes	598.50	369.16
Working capital movements:		
Inventories	(52.58)	33.33
Trade receivables	12.05	(8.09)
Other assets (current and non-current)	25.58	(68.29)
Trade payables	35.63	(6.24)
Provisions	(9.97)	(20.35)
Other liabilities (current and non-current)	(85.21)	3.41
Cash generated from operating activities	524.01	302.92
Taxes paid (Net)	(84.62)	(29.87)
Net cash generated from operating activities (A)	439.39	273.05
B.Cash flows from investing activities		
Purchase of property, plant and equipment	(468.49)	(47.57)
Proceeds from the sale of property, plant and equipment	1.95	35.52
Interest income	45.00	39.10
Rental income	29.75	21.50
Net cash generated from / (used in) investing activities (B)	(391.79)	48.54
C.Cash flows from financing activities		
Finance costs	(12.81)	(5.63)
Dividend paid	(103.36)	-
Payment of lease liabilities	(41.37)	(26.28)
Net cash (used in) / generated from financing activities (C)	(157.54)	(31.91)
Net increase / (decrease) in cash and cash equivalents (A+B+C)	(109.94)	289.69
Cash and cash equivalents at the beginning of the year	989.24	699.55
Cash and equivalents at the end of the year	879.30	989.24
Cash on hand	6.08	8.54
Balance with banks	873.22	980.70

Note:

1. Cash and bank balances do not include balance maintained in unpaid dividend account - Rs.5.44 lakhs (FY20-21 : Rs. 2.08 lakhs) but which has been shown under "Cash and cash equivalents" in the balance sheet.

Coimbatore,
May 25, 2022.

For Lotus Eye Hospital & Institute Limited

Sangeetha

Ms. S. SANGEETHA
Managing Director - DIN : 01859252



Lotus Eye Hospital And Institute Limited

CIN No. : L85110TZ1997PLC007783

770/12, Avinashi Road, Civil Aerodrome Post, Coimbatore - 641 014.

Tel : 0422 - 4229900, 4229999 Fax : 0422 - 4229933



R.S. PURAM

155B, East Periasamy Road, Near Chinthamani,
North Coimbatore, R.S. Puram,
Coimbatore - 2. Phone : 0422 - 4239900, 4239999

METTUPPALAYAM

No. 28, Coimbatore Main Rd,
Opp. Bus Stand, MTP - 634 301.
Phone : 04254 - 223223, 224224

TIRUPUR

No. 5(2) Gajalakshmi Theatre Road (Backside)
Near Valarmathi Bus Stop, Tirupur - 641 601.
Phone : 0421 - 4346060, 4219999

SALEM

86, Brindhavan Road, Fairlands
Salem - 636 004.
Ph. : 0427 - 4219900, 4219999

E-mail : info@lotuseye.org

Website : www.lotuseye.org

May 25 2022

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Scrip Code: 532998	National Stock Exchange of India Limited 5th Floor, Exchange Plaza Bandra (East) Mumbai – 400 051 Scrip Code: LOTUSEYE
---	---

DECLARATION

Pursuant to the provisions of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/56/2016 dated May, 27, 2016 on "Disclosure of the Impact of Audit Qualification by Listed Entity", we hereby confirm and declare that Anbarsu & Jalapathi, Chartered Accountants (Fim Registration No. 0107958), the Statutory Auditors of the Company, have issued the Audit Report with unmodified opinion with respect to Audited Financial Results of the Company for the quarter and year ended 31st March, 2022

For Lotus Eye Hospital & Institute Limited

Sangeetha Sundaramoorthy
Managing Director
DIN:01829252

Kochi

533/33A-33F, Tejas Tower
SA Road, Kadavanthara,
Kochi, Kerala - 682 020.
Tel. : 0484 - 2322333, 2322444

Kochi

229A, Kurisingal House
Mula:thuruty Post
Kochi, Kerala - 682 314.
Tel. : 0484 - 2743191, 2743121

Always for you



Lotus Eye Hospital And Institute Limited

CIN No. : L85110TZ1997PLC007783

770/12, Avinashi Road, Civil Aerodrome Post, Coimbatore - 641 014.

Tel : 0422 - 4229900, 4229999 Fax : 0422 - 4229933



R.S. PURAM

155B, East Periasamy Road, Near Chinthamani,
North Coimbatore, R.S. Puram,
Coimbatore - 2. Phone : 0422 - 4239900, 4239999

METTUPPALAYAM

No. 28, Coimbatore Main Rd,
Opp. Bus Stand, MTP - 634 301.
Phone : 04254 - 223223, 224224

TIRUPUR

No. 5(2) Gajalakshmi Theatre Road (Backside)
Near Valarmathi Bus Stop, Tirupur - 641 601.
Phone : 0421 - 4346060, 4219999

SALEM

86, Brindhavan Road, Fairlands
Salem - 636 004.
Ph. : 0427 - 4219900, 4219999

E-mail : info@lotuseye.org

Website : www.lotuseye.org

May 25, 2022

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Scrip Code: 532998	National Stock Exchange of India Limited 5th Floor, Exchange Plaza Bandra (East) Mumbai – 400 051 Scrip Code: LOTUSEYE
---	---

Sub.: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Please find enclosed herewith disclosure of related party transactions for the half-year ended March 31, 2022 pursuant to Regulation 23(9) of the Listing Regulations, in the format specified by SEBI vide circular SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021.

We request you to please take the same on your record. Thanking You.

For Lotus Eye Hospital & Institute Limited

M Achuth Menon
Company Secretary & Compliance Officer
Membership No-A63980

Kochi

533/33A-33F, Tejas Tower
SA Road, Kadavanthara,
Kochi, Kerala - 682 020.
Tel. : 0484 - 2322333, 2322444

Always for you

Kochi

229A, Kurisingal House
Mula:thuruty Post
Kochi, Kerala - 682 314.
Tel. : 0484 - 2743191, 2743121

Format for disclosure of related party transactions every six months (see Note 4)

S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty		Type of related party transaction (see Note 5)	Value of the related party transaction as approved by the audit committee (see Note 6a)	Value of transaction during the reporting period (see Note 6b)	In case monies are due to either party as a result of the transaction (see Note 7)		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments				Purpose for which the funds will be utilised by the ultimate recipient of funds (and-usage)
	Name	PAN	Name	PAN				Relationship of the counterparty with the listed entity or its subsidiary	Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost (see Note 7)	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	
1.	LEHIL*		LVRT#		MD of LEHIL is Managing Trustee of LVRT	33 Lakhs	16,50 Lakhs	-	-	NA	NA	NA	NA	NA	NA	NA	NA	
2.	LEHIL*		LVRT#		MD of LEHIL is Managing Trustee of LVRT	71 Lakhs	28,95 Lakhs	-	-									
3.	LEHIL*		Combinatoric Kidney Centre		CEO is Managing Director of Combinatore Kidney Centre	12 Lakhs	1,65 Lakhs	-	-									
4.	LEHIL*		Sangeetha Sundaram Coorty		Promoter/Managing Director	-	6 Lakhs	-	-									
5.	LEHIL*		KS Ramalingam		Key Managerial Personnel	-	6 Lakhs	-	-									

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

6	LEHIL*	Kavetha Sundaramoorthy	Promoter	Sitting Fees	-	0.5 Lakhs	-	-											
7	LEHIL*	DR Kaarthikeyan	Director	Sitting Fees	-	1 lakhs	-	-											
8	LEHIL*	Yogesh shah	Director	Sitting Fees	-	0.5 Lakhs	-	-											
9	LEHIL*	R Subramanian	Director	Sitting Fees	-	1 lakhs	-	-											
10	LEHIL*	S Nagesan	Director	Sitting Fees	-	1 lakhs	-	-											
11	LEHIL*	Alagiriswamy	Director	Sitting Fees	-	1 lakhs	-	-											
12	LEHIL*	Achuth menon	Company Secretary Appointed w.e.f from 04.02.2022	Employee Benefit Expenses	-	1.39 Lakhs	-	-											
13	LEHIL*	A Ganesh	Ex-CFO Ceased with Effect from 25.03.2022	Employee Benefit Expenses	-	8.4 Lakhs	-	-											
14	LEHIL*	Aakansha Parmar	Company Secretary Ceased with Effect from 30.10.2021	Employee Benefit Expenses	-	0.63lakhs	-	-											
15	LEHIL*	LVRT#	M.D of LEHIL is Managing Trustee of LVRT	Sale of Fixed Assets	-	0.84 lakhs	-	-											

*Lotus Eye Hospital and Institute Limited
Lotus Vision Research Trust



Independent Auditors' Report

To
The Board of Directors
Lotus Eye Hospital and Institute Limited,
CIN: L85110TZ1997PLC007783.

Report on the audit of annual financial results

Opinion

We have audited the accompanying annual financial results of Lotus Eye Hospital and Institute Limited (herein referred to as the "Company") for the year ended March 31, 2022 being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") as amended.

In our opinion and to the best of our information and according to the explanation given to us, the aforesaid annual financial results:

- are presented in accordance with the requirement of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, as applicable and other generally accepted accounting principles in India, of the net profit and other comprehensive income and other financial information for the year ended March 31, 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") issued by the Institute of Chartered Accountants of India ("ICAI"), prescribed by Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are described in the *Auditor's Responsibilities for the Audit of Financial Results* section of this report. We are independent of the Company, in accordance with the Code of Ethics issued by ICAI together with the ethical requirements that are relevant to our audit of the financial statements, under the provision of the Act and the Rules thereunder. We have fulfilled our other ethical requirements in accordance with the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for opinion on the annual financial results.

Management's and Board of Director's Responsibilities for the Annual Financial Results

These annual financial results have been prepared on the basis of the annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these annual financial results that give a true and fair view of the net profit and



other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder as applicable and other generally accepted accounting principles in India and in compliance with Regulation 33 of the Listing Regulations. The respective management and board of directors are responsible for the maintenance of adequate accounting records to comply with the provisions of the Act and to safeguard the assets of the Company and for preventing and detecting frauds and other irregularities, selection and application of appropriate accounting policies, making judgements and estimates that are reasonable and prudent, and the design, implementation and maintenance of adequate internal financial controls, that are operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the annual financial results, the respective Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls



with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the annual financial results, including the disclosures, and whether the annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The aforesaid annual financial results include the results for the quarter ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For Anbarasu & Jalapathi
Chartered Accountants
Firm Registration No.: 0107955

S. Anbarasu
Partner

Membership No.: 212299

Coimbatore,
May 25, 2022.

UDIN: 22212299AJPTGA817D